Whether we have the funds to run it ourselves I guess depends on the design of the trial but I think you are right, the decision will rule out anyone other than that partner in making a takeover bid.
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Annual Report to shareholders
NEU
neuren pharmaceuticals limited
Add to My Watchlist
2.30%
!
$13.15

Ann: 2023 Annual Report to shareholders, page-58
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.15 |
Change
0.295(2.30%) |
Mkt cap ! $1.635B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.660M | 355.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 44 | $13.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.15 | 594 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12 | 13.140 |
7 | 129 | 13.130 |
9 | 742 | 13.120 |
12 | 1779 | 13.110 |
5 | 1322 | 13.100 |
Price($) | Vol. | No. |
---|---|---|
13.150 | 231 | 1 |
13.160 | 803 | 6 |
13.170 | 1154 | 7 |
13.180 | 6765 | 13 |
13.190 | 2485 | 10 |
Last trade - 13.00pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
SPONSORED BY The Market Online